Myeloma and CAR T Cells: A Hidden Battle
Unraveling resistance: Genetic and Epigenetic Silencing of GPRC5D Drives Relapse After CAR T-Cell Therapy
Table of Contents
New research published in Blood sheds light on the mechanisms behind treatment failure in multiple myeloma patients who relapsed after GPRC5D CAR T-cell therapy, identifying genetic inactivation and epigenetic silencing as key culprits.
Xuzhou, China - A groundbreaking study has identified critical genetic and epigenetic mechanisms responsible for the loss of GPRC5D expression, a common target in CAR T-cell therapy for multiple myeloma (MM), leading to treatment resistance and relapse. The findings,published in the journal Blood,offer crucial insights for developing more effective therapeutic strategies against this challenging hematological malignancy.
The research focused on ten patients who relapsed after receiving GPRC5D-targeted CAR T-cell therapy. The analysis involved meticulous examination of bone marrow samples, with a particular focus on CD138+ multiple myeloma cells, ensuring a high purity of over 80%. Tumor samples were sequenced at a depth of 100× coverage, while matched normal samples were analyzed at 30× coverage. To further investigate the regulatory landscape of GPRC5D, investigators employed targeted bisulfite sequencing to assess methylation status across key regulatory regions in seven MM cell lines.This specialized sequencing was performed by dedicated institutes, underscoring the rigor of the study’s methodology.
The patient cohort comprised individuals with a median age of 57.5 years, ranging from 44 to 66 years. The gender distribution was equal, and a significant 90% of patients presented with high-risk cytogenetic abnormalities, indicating a more aggressive disease profile.
Key Findings: Mechanisms of GPRC5D Loss
The complete analysis revealed several critical genetic and epigenetic alterations contributing to GPRC5D loss and subsequent relapse:
Genetic Alterations: Genetic modifications were identified in three of the ten patients. One patient exhibited a homozygous deletion within the GPRC5D gene itself. Another patient displayed a biallelic loss affecting the regulatory regions crucial for GPRC5D expression. A third patient,who had undergone sequential anti-B-cell maturation antigen (BCMA) and anti-GPRC5D CAR T-cell therapies,showed homozygous deletions in both the TNFRSF17 (BCMA) and GPRC5D genes.
Epigenetic Silencing: In five post-treatment multiple myeloma samples, multiple hypermethylation sites were detected within the transcriptional regulatory elements of the GPRC5D gene. Notably, in seven cases, no genetic changes were found at the GPRC5D locus, strongly suggesting epigenetic mechanisms as the primary driver of GPRC5D loss in these individuals.
Inverse Correlation and Reversal: The study demonstrated an inverse correlation between GPRC5D expression levels and methylation status in the regulatory regions of MM cell lines. Furthermore,treatment with azacitidine,a hypomethylating agent,successfully induced GPRC5D messenger RNA (mRNA) and protein expression in MM cell lines that exhibited hypermethylation. This finding highlights the potential of epigenetic reprogramming to restore target expression.
Treatment Response and Progression: Despite the mechanisms of resistance,all ten patients achieved a complete response (CR) or better as their best response to GPRC5D CAR T-cell therapy. The median time to best response was a rapid 2.5 months (range, 0.5-15.3 months). However, the median time to disease progression was 15.9 months (range, 3.0-26.5 months), underscoring the challenge of durable remission.
Implications for Clinical Practice
“Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance,” stated the authors of the study. This understanding is paramount for clinicians and researchers aiming to overcome therapeutic hurdles in multiple myeloma. The identification of these resistance mechanisms opens avenues for developing strategies to prevent or reverse GPRC5D loss, potentially through combination therapies that target both genetic and epigenetic pathways, or by employing agents like azacitidine to re-sensitize tumors to CAR T-cell therapy.
Study Limitations and Future Directions
The authors acknowledge certain limitations in their study. Structural variant deletions on chromosomes might have been missed by whole-genome sequencing (WGS) at 100× coverage if the clone size was less than 20%. Additionally, the sensitivity limitations of quantitative polymerase chain reaction (qPCR), with a limit of detection ranging from 16 to 50 copies per